{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:23:37Z","timestamp":1792268617868,"version":"4.4.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40265-025-02271-0","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T06:54:04Z","timestamp":1766040844000},"page":"391-396","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Zeprumetostat: First Approval"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0121-7645","authenticated-orcid":false,"given":"Susan J.","family":"Keam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"issue":"7","key":"2271_CR1","doi-asserted-by":"publisher","first-page":"e463","DOI":"10.1016\/S2352-3026(22)00169-7","volume":"9","author":"YK Ryu","year":"2022","unstructured":"Ryu YK, Amengual JE. Easy does it! New EZH2 inhibitor SHR2554 is safe and active in relapsed or refractory lymphoma. Lancet Haematol. 2022;9(7):e463\u20135.","journal-title":"Lancet Haematol"},{"key":"2271_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17193111","author":"S Verma","year":"2025","unstructured":"Verma S, Goyal N, Goyal S, et al. EZH2 dysregulation and its oncogenic role in human cancers. Cancers. 2025. https:\/\/doi.org\/10.3390\/cancers17193111.","journal-title":"Cancers"},{"key":"2271_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29245817","author":"MSG Montani","year":"2024","unstructured":"Montani MSG, Benedetti R, Cirone M. Targeting EZH2 in cancer: mechanisms, pathways, and therapeutic potential. Molecules. 2024. https:\/\/doi.org\/10.3390\/molecules29245817.","journal-title":"Molecules"},{"issue":"3","key":"2271_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2024.101313","volume":"12","author":"M Xu","year":"2025","unstructured":"Xu M, Xu C, Wang R, et al. Treating human cancer by targeting EZH2. Genes Dis. 2025;12(3):101313.","journal-title":"Genes Dis"},{"issue":"3","key":"2271_CR5","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.18632\/oncotarget.6198","volume":"7","author":"L Herviou","year":"2016","unstructured":"Herviou L, Cavalli G, Cartron G, et al. Ezh2 in normal hematopoiesis and hematological malignancies. Oncotarget. 2016;7(3):2284\u201396.","journal-title":"Oncotarget"},{"key":"2271_CR6","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. T-Cell lymphomas: version 2.2025. 2025. https:\/\/www.nccn.org\/. Accessed 8 Oct 2025."},{"key":"2271_CR7","unstructured":"Jiangsu Hengrui Pharmaceuticals Co Ltd. First patient dosed in a pivotal study of Hengrui's novel EZH2 inhibitor (SHR2554) for the treatment of peripheral T-cell lymphoma [media release]. 13 Dec 2021. https:\/\/www.hengrui.com\/."},{"key":"2271_CR8","unstructured":"Jiangsu Hengrui Pharmaceuticals Co Ltd. Zeprumetostat: Chinese prescribing information. 2025. https:\/\/www.hengrui.com\/. Accessed 2 Oct 2025."},{"key":"2271_CR9","unstructured":"National Medical Products Administration. NMPA Approval notice. 2025. https:\/\/www.nmpa.gov.cn\/. Accessed 2 Oct 2025."},{"key":"2271_CR10","unstructured":"Jiangsu Hengrui Pharmaceuticals Co Ltd. Hengrui's innovative drug \u827e\u745e\u749f\u00aehas been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma [media release]. 3 Sep 2025. https:\/\/www.hengrui.com\/."},{"key":"2271_CR11","unstructured":"Jiangsu Hengrui Pharmaceuticals Co Ltd. Hengrui Medicine's \"Double Ai\" combination for the first-line treatment of liver cancer has been accepted by the FDA for US marketing approval [media release]. 1 Aug 2023. https:\/\/www.hengrui.com\/."},{"key":"2271_CR12","unstructured":"Jiangsu Hengrui Pharmaceuticals Co. L. Hengrui Medicine's innovative drug SHR2554 research results were published in The Lancet Haematology, potentially providing new options for patients with relapsed or refractory lymphoma [media release]. 27 Jul 2022. https:\/\/www.hengrui.com\/."},{"issue":"7","key":"2271_CR13","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1016\/S2352-3026(22)00134-X","volume":"9","author":"Y Song","year":"2022","unstructured":"Song Y, Liu Y, Li ZM, et al. SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial. Lancet Haematol. 2022;9(7):e493\u2013503.","journal-title":"Lancet Haematol"},{"key":"2271_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115154","volume":"162","author":"J Li","year":"2025","unstructured":"Li J, Hua H, Liu X, et al. Inhibition of EZH2 by SHR2554 modifies subset ratios and suppresses polyfunctional responses of peripheral blood T cells from hematopoietic stem cell donors. Int Immunopharmacol. 2025;162:115154.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"2271_CR15","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/s41419-025-07775-x","volume":"16","author":"J Wu","year":"2025","unstructured":"Wu J, Hu D, Yu H, et al. Ezh2 inhibitor SHR2554 enhances the anti-tumor efficacy of HDAC inhibitor chidamide through STAT1 in T-cell lymphoma. Cell Death Dis. 2025;16(1):522.","journal-title":"Cell Death Dis"},{"key":"2271_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174249","author":"X Wang","year":"2021","unstructured":"Wang X, Wang D, Ding N, et al. The synergistic anti-tumor activity of EZH2 inhibitor SHR2554 and HDAC inhibitor chidamide through ORC1 reduction of DNA replication process in diffuse large B cell lymphoma. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13174249.","journal-title":"Cancers (Basel)"},{"issue":"S3","key":"2271_CR17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/hon.70093_61","volume":"43","author":"Y Song","year":"2025","unstructured":"Song Y, Li Z, Jin Z, et al. A pivotal study of SHR2554, an oral inhibitor against enhancer of zeste homolog 2 (EZH2), in relapsed or refractory (R\/R) peripheral t-cell lymphoma (PTCL) [abstract no. 61 plus presentation]. Hematol Oncol. 2025;43(S3):63\u20134.","journal-title":"Hematol Oncol"},{"issue":"7","key":"2271_CR18","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1158\/1078-0432.CCR-23-2582","volume":"30","author":"Y Song","year":"2024","unstructured":"Song Y, Jin Z, Li ZM, et al. Enhancer of Zeste Homolog 2 inhibitor SHR2554 in relapsed or refractory peripheral T-cell lymphoma: data from the first-in-human phase I study. Clin Cancer Res. 2024;30(7):1248\u201355.","journal-title":"Clin Cancer Res"},{"key":"2271_CR19","doi-asserted-by":"crossref","unstructured":"Feng K, Liu Y, Wang C, et al. Phase I study of the bifunctional anti-PD-L1\/TGF-[beta]RII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors [abstract no. 2507]. J Clin Oncol. 2023;41(16 Suppl).","DOI":"10.1200\/JCO.2023.41.16_suppl.2507"},{"key":"2271_CR20","doi-asserted-by":"crossref","unstructured":"Zhou Y, Ding X, Zhang Y, et al. Efficacy and safety of SHR-2554 in advanced epithelioid sarcoma: a phase 2 trial [abstract no. 11549]. J Clin Oncol. 2024;42(16 Suppl).","DOI":"10.1200\/JCO.2024.42.16_suppl.11549"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02271-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02271-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02271-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:35:48Z","timestamp":1772764548000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02271-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2271"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02271-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"12 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, consent to participate, consent to publish, availability of data and material, code availability"}}]}}